VC
KITE

Vivo Capital’s Kite Pharma, Inc. KITE Stock Holding History

Vivo Capital’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-193,193
Closed -$8.87M – 25
2016
Q1 		$8.87M Buy
+193,193
New +$9.36M 2.22% 14

Other funds holding KITE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vivo Capital's KITE Position: Q2 2016 in Review

Vivo Capital sold out of Kite Pharma, Inc. (KITE) in Q2 2016, closing a stake of 193,193 shares — an estimated $8.87M sold.

Vivo Capital first reported a position in KITE in Q1 2016 and held it in 1 quarter. The position peaked at $8.87M in Q1 2016. 173 funds tracked by Wall St. Rank hold KITE as of Q2 2016.

  • Vivo Capital reported no remaining Kite Pharma, Inc. position as of Q2 2016 after selling out during the quarter.
  • Vivo Capital sold 193,193 Kite Pharma, Inc. shares in Q2 2016, an estimated $8.87M.
  • Vivo Capital first reported a position in Kite Pharma, Inc. in Q1 2016 and held it in 1 quarter.
  • Vivo Capital's Kite Pharma, Inc. position peaked at $8.87M in Q1 2016.
  • 173 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2016.

Based on Vivo Capital's 13F filing for Q2 2016, filed 15 Aug 2016.